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ABSTRACT: 12 
 13 
Capillary electrophoresis mass spectrometry coupling (CE-MS) is a growing technique 14 
in biopharmaceutics characterization. Assessment of monoclonal antibodies (mAbs) is well 15 
known at middle-up and bottom-up levels to obtain information about the sequence, post-16 
translational modifications (PTMs) and degradation products. Intact protein analysis is an 17 
actual challenge to be closer to the real protein structure. At this level, actual techniques are 18 
time consuming or cumbersome processes. In this work, a 20 minutes separation method has 19 
been developed to optimize characterization of intact mAbs. Thus, separation have been done 20 
on a positively-charged coated capillary (PEI) with optimized volatile background electrolyte 21 
(BGE) and sample buffer (SB). A sheathless interface allowed to hyphenate CE to a quadrupole-22 
time-of-flight mass spectrometer (Q-TOF) which parameters has been tuned to improve the 23 
high masses detection and identification of intact mAbs. Three world-wide health authorities 24 
approved mAbs have been used to set up a rapid and ease of use method. Intact trastuzumab, 25 
rituximab and palivizumab isoforms have been partially separated with this method in less 26 
than 20 minutes under denaturing conditions. For each mAb, 2X-glycosylated and 1X-27 
glycosylated structures have been identified and separated. Concerning basic and acidic 28 
variants potential Iso-Asp modification and Asn deamidation have been observed. Accurate 29 
mass determination for high-mass molecular species remains a challenge, but the progress in 30 
intact mAbs separation appears very promising for biopharmaceutics characterization. 31 
 32 
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Introduction 41 
Monoclonal antibodies (mAbs) are tetrameric glycoproteins having a molecular mass of 42 
approximately 150 kDa, composed of two heavy chains and two light chains, inter-linked by several 43 
disulfide bonds, and having at least one conserved N-glycosylation site located in the Fc domain1. mAbs 44 
were introduced for the treatment of various diseases in the late 1980 and they still represent the most 45 
rapidly growing category of therapeutic molecules today1-3. There are more than seventy-five mAbs 46 
approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). 47 
mAb are particularly interesting because of their good therapeutic efficiency, favorable 48 
pharmacokinetic (PK) and pharmacodynamics (PD), and relatively low side-effects4.  49 
Several separation-based methods both on liquid chromatography and electrophoresis are used for 50 
antibody characterization and homogeneity assessment5. These orthogonal analytical methods aim 51 
particularly to separate the antibody main isoform from micro-variants6. Micro-variants are commonly 52 
observed when mAbs are analyzed by charge-based separation techniques such as isoelectric focusing 53 
gel electrophoresis (IEF), capillary IEF (cIEF), imaged cIEF (icIEF), capillary zone electrophoresis (CZE) 54 
and ion exchange chromatography (CEX/ AEX)7. Many of the modifications leading to the formation of 55 
acidic and basic species have been identified as asparagines (Asn) deamidation, methionines oxidation, 56 
aspartic acid isomerization (Iso-Asp), cyclization of glutamic acid or glycosylation. mAb heterogeneity 57 
explains the difficulty of separation and identification of each isoform. In a theoretical way, millions of 58 
possibilities are available for only one mAb with plenty of weak masses difference between 59 
proteoforms. Most of these PTMs have been localized and characterized by different techniques as 60 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) or capillary electrophoresis-tandem 61 
mass spectrometry coupling (CE-MS/MS)5, 8-10. LC-MS/MS and CE-MS/MS analysis, built on a classical 62 
bottom-up proteomics strategy, allowed to get a lot of information about mAbs proteoforms and their 63 
PTMs but workflows can induce some modifications or degradations of therapeutic proteins. 64 
This last decade, separation of intact mAbs have been studied with several electrophoretic 65 
techniques such as CZE, 2D-CE-MS and CZE-MS11-14. He et al were precursor in the field of intact mAbs 66 
separation using CZE-UV. They developed a rapid method using ε-amino-caproic acid (EACA) and 67 
triethylenetetramine (TETA) as BGE, and hydroxypropylmethyl cellulose (HPMC) as dynamic neutral 68 
coating of the capillary11, 15. In 2015 Moritz et al validated this method by an inter-laboratory study 69 
allowing to consider it as the reference method for charge heterogeneity assessment of mAbs16. Other 70 
approach using UV detection was recently described by Goyon et al to set up a simpler CZE method to 71 
separate more acidic and basic variants for a dozen of commercial mAbs17. However, the composition 72 
of BGEs described in these studies are not compatible with ESI-MS detection due to high salt 73 
concentration and the presence of detergents and polymers. Since 2017, Neusüβ’s group developed 74 
an original 2D-CE-MS instrumentation allowing the separation of intact mAbs by CZE-CZE-MS and icIEF-75 
CZE-MS18, 19. While the first CZE dimension enabling to use the same BGE condition as the reference 76 
CZE-UV method described by He et al15, the second dimension allowed the MS characterization by the 77 
use of BGEs compatible with ESI-MS detection. Jooβ et al illustrated their method for the detailed MS 78 
characterization of mAbs charge variants18. They highlighted glycosylated and deglycosylated variants 79 
and potential deamidation products for an intact antibody. While this approach appears very 80 
promising, CZE-CZE-MS setup needed heavy instrumental development and the overall analysis time 81 
is rather long. More recently, Belov et al developed a CZE-ESI-MS method to characterize one unknown 82 
IgG1 mAb by both middle-down and intact levels. At the intact level, CZE-ESI-MS analysis were 83 
performed under denaturing conditions and using a non-commercial positive coating (M7C4I). Baseline 84 
separation of the 2X-glycosylatd, 1X-glycosylated, and aglycosylated populations were obtained in 85 
nearly 30 minutes20.  86 
In this report, we developed a 20 minutes CZE-ESI-MS method for the analysis of three well-known 87 
approved mAbs at the intact level. Experiments were performed with a commercial positively-charged 88 
capillary coating of polyethyleneImine (PEI) to avoid adsorption phenomenon. Acidic background 89 
electrolyte (BGE) and acidic methanol/water sample buffer have been optimized in order to obtain 90 
micro-variants separation of intact mAbs in less than 20 minutes. Three world-wide health authorities 91 
approved mAbs: rituximab (chIgG1, CHO), palivizumab (hzIgG1, SP2/0) and trastuzumab (hzIgG1, CHO), 92 
were selected for this study. Comparison with reference CZE-UV methods have been achieved allowing 93 
potential characterization of basic and acidic variant regions. Separation of charge variants arising from 94 
2X-glycosylated, 1X-glycosylated pattern has been identified while potential Iso-aspartic acid 95 
isomerization (Iso-Asp) and asparagine deamidation have been observed as basic and acidic variants.  96 
 97 
Experimental 98 
 99 
Chemicals 100 
Chemicals used were of analytical grade or high purity grade and purchased from Sigma-Aldrich (Saint 101 
Louis, MO, USA). Water used to prepare buffers and sample solutions was obtained using an ELGA 102 
purelab UHQ PS water purification system (Bucks, UK). mAbs were obtained as European Union 103 
pharmaceutical-grade drug product from their respective manufacturers. 104 
 105 
Sample preparation 106 
For intact mAbs analysis; trastuzumab, rituximab and palivizumab were desalted to remove all residual 107 
components of the storage solution. Samples were buffer exchanged with milliQ water three times on 108 
Amicon centrifugal filters with a 10 kDa cut off (Merck, Darmstadt, Germany). Each centrifugation was 109 
made at 14’000 g speed during 20 min to claw back 30 µL of mAbs at a concentration of 33.3 µM. 110 
Samples were led to a final concentration in protein of 6.7 µM using the desired sample buffers. 111 
 112 
Capillary electrophoresis 113 
All of the CE experiments have been done on a CESI8000 capillary electrophoresis system from Sciex 114 
Separation (Brea, CA, USA). Bare fused-silica capillaries (total length 100 cm; 30 µm i.d.) with a porous 115 
end from Sciex Separation (Brea, CA, USA) were positively coated with a commercial 116 
PolyEthyleneImine (PEI) coating following the protocol provided by Sciex Separation. A second capillary 117 
(total length 80 cm; 50 µm i.d.) was used to complete the electric line of the separation system. Before 118 
each analysis, both capillaries were rinsed at 75 psi during 3 min with 3% acetic acid BGE. The 32 119 
KaratTM (Sciex Separation) software was used for instrument control and data acquisition. 120 
Hydrodynamic injection (2 psi for 10 sec) corresponding to a volume of 3 nL (0.5% of the capillary 121 
length) was used to inject the sample.  122 
 123 
Mass spectrometry 124 
The CE system was hyphenated to a maXis 4G (Bruker, Bremen, Germany) by the sheathless interface. 125 
This MS instrument is equipped with a hybrid analyzer composed of hexapoles followed by a time-of-126 
flight (TOF) analyzer. Sample were run in denaturating conditions and analyzed in a m/z range from 127 
2500 to 5000. The Otof control 3.4 software allowed to pilot the nano-ESI source and the settings were 128 
the following ones: nanoESI voltage +1500 V, dry gas 3 L/min, ion funnels set at values of 400 and 400 129 
Vpp, isCID energy at 190 eV and source temperature at 150°C. The data acquisition was made in 130 
positive mode.  131 
 132 
Data analysis 133 
MS data have been analyzed with the dissect mode of Data Analysis 4.2 software (Bruker, Bremen, 134 
Germany) with an internal S/N threshold of 3 and a maximum of 10 overlapping compounds. Cut-off 135 
intensity of mass spectrum calculation was set at 0.1 %. After an automatic interpretation of the 136 
results, a manual validation has been performed on the results. MS spectra have been extracted from 137 
each peak represented on the BPE (Base Peak Electropherogram). Each profile has been selected and 138 
deconvoluted between 140 and 160 KDa with the maximum entropy algorithm provided by Bruker’s 139 
software to calculate the mass of the corresponding compounds. Automatic and manual results have 140 
been confronted to detect any mass modifications and get some additional information about the 141 
different identified compounds.  142 
 143 
Results and discussion 144 
In this work, major separation parameters have been selected and optimized based on the 145 
agreement of intact mAbs analysis and limits of CE-MS coupling. To avoid protein adsorption on the 146 
inner surface of the capillary due to negative charge surface of the silanol groups, bare fused silica 147 
capillaries have been previously modified with a covalent coating of PEI which confers positive charge 148 
surface of the inner capillary wall and then involves a reverse electro-osmotic flow under an electric 149 
field. Online CZE-ESI-MS coupling excluding the use of non-volatile salts11, effects of volatile 150 
background electrolyte (BGE), sample buffer and injection volume were optimized on the separation 151 
of intact trastuzumab. This mAb can be considered as reference material for CZE-ESI-MS method 152 
development due to the large number of reports describing the physicochemical properties of the 153 
protein7.  154 
 155 
Evaluation of BGE and sample buffer component effect on method development 156 
 157 
The most frequently used BGEs in CZE-ESI-MS under denaturing conditions are acetic acid and formic 158 
acid because of their conductivity and their volatility allowing a good compatibility with ESI-MS 159 
detection20-23. In our study, BGEs consisted in acetic acid and formic acid at different concentrations 160 
from 1 to 10 % (v/v) and 1 to 5 % (v/v) respectively, were evaluated to keep a current intensity 161 
compatible with the separation and to avoid any degradation of capillaries. No separation has been 162 
observed with formic acid BGEs in the tested conditions. Concerning acetic acid, increasing 163 
concentration from 1 to 10 % induced a time shift for the compounds migration (Figure 1) due to the 164 
increase of ionic strength. 1% and 10% showed only one peak meaning that no separation of mAbs 165 
isoforms can be observed. However, 3 and 5 % acetic acid gave partial separation of mAbs with poor 166 
resolution. Indeed, obtained peaks were not thin and resolved and deconvolution spectra showed 167 
partial overlapping of different isoforms. However, 3 % acetic acid BGE gave the most encouraging 168 
separation of intact mAbs and was conserved to the next optimization step.  169 
 170 
Figure 1. Effect of acetic acid concentration on the separation of trastuzumab charge variants. Acetic 171 
acid proportion was set up at 1%, 3%, 5% and 10%.  172 
 173 
Sample buffer is a parameter which can increase the performance of the separation, for instance due 174 
to difference of conductivity with BGE. The first part of this optimization step consisted in testing 175 
purified water, acetic acid and formic acid at different concentrations (1 to 10 % (v/v) and 1 to 5 % 176 
(v/v) respectively) as sample buffer. Obtained results with purified water and acetic acid showed no 177 
increase of resolution in mAbs separation. Only formic acid gave better resolution partly due to the 178 
sharpness of the peaks, however, no tremendous increase of separation has been observed. 179 
Nevertheless, 1% formic acid has been selected for the following steps. Based on the work of Schwer 180 
et al who have calculated the influence on the electroosmotic velocity of adding organic solvent to the 181 
electrolytes24, we assessed the addition of methanol at different ratio (10 to 50% (v/v)) in the 1% formic 182 
acid sample buffer (Figure 2). Up to 30 % Methanol, a partial separation was obtained while a total loss 183 
of resolution was observed for ratio above 30%. Trastuzumab separation performed with 30 % 184 
methanol, 1% formic acid sample buffer exhibited three peaks obtained in less than 15 minutes (RSD 185 
< 3% on migration times (n=10)). Other organic solvents have been investigated as acetonitrile and 186 
isopropanol in the same proportions, however only methanol has given some good results. Sample 187 
injection volume has also been studied to subvert a capillary overloading known to affect the 188 
separation of compounds. Trials were done from 1 to 20 nL corresponding to 7 to 350 fmol of mAbs. 189 
Better results were obtained by injecting 3 nL (20 fmol) of trastuzumab in the PEI coated capillary. 190 
 191 
Figure 2. Effect of methanol concentration in the sample buffer for the separation of trastuzumab 192 
charge variants. Methanol proportion was set up at 10%, 20%, 30%, 40%, 50% and 70% on 1% formic 193 
acid (v/v). The BGE contained 3% acetic acid. 194 
 195 
CZE-ESI-MS characterization of intact mAbs  196 
Since 2010, a some reports described CZE-based methods for the characterization of mAbs 197 
charges variants for the quality control of biopharmaceutical companies in terms of product 198 
heterogeneity11-14, 18. To date, two reports from Ruesch’s group represents a reference for the analysis 199 
of mAbs using CZE with a UV detection 11, 15. Nevertheless, no structural information can be detailed 200 
for the basic and/or acidic variants. In our study, optimized CZE-ESI-MS condition developed on 201 
trastuzumab sample has been assessed on two other well-known IgG1 mAbs: rituximab and 202 
palivizumab. Obtained results for these three mAbs are showed in Figure 3. Due to the reverse 203 
electroosmotic mode involved by the use of PEI coated capillary, electropherograms of each mAbs 204 
exhibited three peaks distributed as acidic variants in the first peak, the main variant in the second 205 
peak and basic variants in the third peak. Despite the worst resolution obtained in CZE-ESI-MS as 206 
compared to reference CZE-UV method which can be easily understood by the difference of BGE 207 
condition (pH 5.7, presence of TETA…) and the inverted profiles of the three regions due to reverse 208 
mode, obtained CZE-ESI-MS electropherograms fitted well with reference CZE-UV electropherograms. 209 
Each mAbs following quite well similar behavior in appearance, trastuzumab has been chosen to 210 
illustrate globally the obtained MS results. However, differences will be detailed for rituximab and 211 
palituzumab. For each peak, deconvoluted mass spectra exhibited the classical glycoform pattern of 212 
trastuzumab (Figure 4). Focused on the three highest abundance glycoforms of the main peak, average 213 
masses of 148,057 ± 3 Da, 148,218 ± 2 Da, and 148,380 ± 3 Da were measured corresponding to 214 
G0F/G0F, G0F/G1F, and G1F/G1F glycoforms respectively. Mass delta of around 162 Da between the 215 
three glycoforms agreed with the theoretical mass of a galactose moiety. However, glycan structure 216 
with the addition of galactose moieties does not induce a change in net charge25-27. Gahoual and co-217 
workers demonstrated that particular glycopeptides having a difference of one galactose could be 218 
baseline separated8 whereas Redman et al did not observe mobility shifts between intact mAb 219 
glycoforms due to the low impact of 162 Da on the global mass of the mAb (≈0.1%)23. Our work follows 220 
Redman et al observations with no separation of intact mAb variants due to differences of 2X-221 
glycosylated forms. However, in each cases, manual analysis of raw data enabled to characterize 1X-222 
glycosylated forms overlapping with the last peak meaning that separation between 2X-glycosylated 223 
and 1X-glyxosylated forms are obtained for the three mAbs. This confirms the results recently 224 
described by Belov et al on an unknown mAbs20.  225 
 226 
 227 
 228 
 229 
Figure 3. CZE-ESI-MS separation of intact tratuzumab, rituximab and palivizumab obtained with the 230 
optimized settings and CZE-UV profiles according to the methodology of He et al 15. Reprinted from 231 
17. Copyright (2018), Wiley. 232 
 233 
For each mAb, peaks corresponding to possible acidic or basic variants have been 234 
deconvoluted. Concerning basic variant, a mass difference of -1 to -2 Da compared with the main 235 
variant was observed for the three mAbs (148,217 ± 4 Da as compared to 148,218 ± 3 Da for 236 
trastuzumab), while a mass difference of -2 Da was observed only for trastuzumab (148,216 ± 4 Da) 237 
for acidic variant. As already described in the literature, the most important antibody basic charge 238 
variants are iso-Asp modification, C-terminal Lys truncation, aglycosylation, incomplete cyclization of 239 
the N-terminal glutamine (Gln) to pyroGlu or methionine oxidation; whereas sialylation, asparagine 240 
deamidation, glycation, cysteinylation are the most commonly observed acidic variants28. Trastuzumab 241 
possesses several Asp and Asn residues in its amino acid sequence which can be potentially iso-Asp or 242 
deamidated10, 29. Even if the standard deviation of mass measurement less than 4 Da doesn’t allow to 243 
conclude without any ambiguity on the exact nature of the modification, we can explain the mass shift 244 
of less than 2 Da by potential iso-Asp modification for basic charge variants and potential Asn 245 
deamidation for acidic charge variants. These results are in agreement with the literature obtained for 246 
the characterization of trastuzumab in a 2D-CZE-MS coupling18. However, while rituximab and 247 
palivizumab also possess potential modified Asn, no acidic variant characterization has been observed 248 
using our CZE-ESI-MS condition. Indeed, for rituximab, third peak deconvoluted mass spectrum gives 249 
any masses corresponding to intact mAbs or degradation products but an unknown impurity, and for 250 
palivizumab, deconvoluted mass spectra fitted with 1X-glycoform pattern. These results can 251 
potentially ask the real nature of acidic variants found by the CZE-UV reference methods for these two 252 
mAbs and highlights the constant need of method development with MS detection to obtained 253 
structural characterization.   254 
 255 
Conclusion 256 
In this study, trastuzumab, rituximab and palivizumab were analyzed at the intact level by CZE-257 
ESI-MS. A rapid separation method has been developed to characterize these commercial mAbs under 258 
denaturating condition. A PEI positive coating has been set up to avoid protein adsorption on the inner 259 
surface of the capillary. Separation has been performed in 3% acetic acid BGE at 30 kV and sample 260 
buffer has been optimized to 30% methanol, 1% formic acid with each mAbs to a final concentration 261 
of 6.7 µM. CZE-ESI-MS analysis of these three mAbs showed partial separation obtained in less than 262 
20 minutes allowing identification of mAbs isoforms. As a first result, CZE-ESI-MS electropherograms 263 
fitted quite well with reference CZE-UV electropherograms allowing a potential characterization of the 264 
basic and acidic variant regions. For each mAbs, 2X-glycosylated and 1X-glycosylated structures has 265 
been identified and separated. Concerning basic and acidic variants, minor differences between 0 to 2 266 
Da have been observed suggesting potential Iso-Asp modification and Asn deamidation. However, 267 
mass precision didn’t allow to conclude without any ambiguity on the nature of these modifications. 268 
Accurate mass determination for high-mass molecular species remains a challenge, but the progress 269 
in intact mAbs separation appears very promising and could be recognized as an additional step in 270 
biopharmaceutics characterization. 271 
 272 
 273 
 274 
 275 
 276 
 277 
 278 
Figure 4. CZE-ESI-MS separation of intact tratuzumab, rituximab and palivizumab obtained with the 279 
optimized settings. For each mAbs, deconvoluted mass spectra was performed for the basic variant 280 
(1), main variant (2), and acidic variant (3) 281 
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